217 related articles for article (PubMed ID: 34692353)
1. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
[TBL] [Abstract][Full Text] [Related]
2. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
3. Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016.
McNamee LM; Cleary EG; Zhang S; Salim U; Ledley FD
Clin Ther; 2021 Jan; 43(1):156-171.e15. PubMed ID: 33380363
[TBL] [Abstract][Full Text] [Related]
4. Company stock prices before and after public announcements related to oncology drugs.
Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
[TBL] [Abstract][Full Text] [Related]
5. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
6. Just how good an investment is the biopharmaceutical sector?
Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
[TBL] [Abstract][Full Text] [Related]
7. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
[TBL] [Abstract][Full Text] [Related]
8. Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016.
Cleary EG; McNamee LM; de Boer S; Holden J; Fitzgerald L; Ledley FD
PLoS One; 2021; 16(1):e0243813. PubMed ID: 33406113
[TBL] [Abstract][Full Text] [Related]
9. Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.
Gentilini A; Parvanova I
BMJ Open; 2023 Jun; 13(6):e071138. PubMed ID: 37369404
[TBL] [Abstract][Full Text] [Related]
10. Financial aspects and the future of the pharmaceutical industry in the United States of america.
Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
[TBL] [Abstract][Full Text] [Related]
11. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
12. Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies.
Amusa G; Feehley T; Bitok JK; Livshits G; Gertsik N
Hum Gene Ther Clin Dev; 2018 Dec; 29(4):179-187. PubMed ID: 30547692
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Vaccines, Healthcare Policies and Stock Markets: Are There Winners and Losers?
Diaz RF; Herrador-Alcaide TC; Sanchez-Robles B
Risk Manag Healthc Policy; 2023; 16():971-989. PubMed ID: 37256165
[TBL] [Abstract][Full Text] [Related]
14. How does news affect biopharma stock prices?: An event study.
Cho J; Singh M; Lo AW
PLoS One; 2024; 19(1):e0296927. PubMed ID: 38277362
[TBL] [Abstract][Full Text] [Related]
15. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
Tyrawski J; DeAndrea DC
J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
[TBL] [Abstract][Full Text] [Related]
17. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
Ledley FD; McCoy SS; Vaughan G; Cleary EG
JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
[TBL] [Abstract][Full Text] [Related]
18. Wise Investment? Modeling Industry Profitability and Risk of Targeted Chemotherapy for Incurable Solid Cancers.
Conter HJ; Chu QSC
J Oncol Pract; 2012 Mar; 8(2):69. PubMed ID: 29447097
[TBL] [Abstract][Full Text] [Related]
19. Do market components account for higher US prescription prices?
Monaghan MJ; Monaghan MS
Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
[TBL] [Abstract][Full Text] [Related]
20. Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies.
López-Toro AA; Sánchez-Teba EM; Benítez-Márquez MD; Rodríguez-Fernández M
Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33923122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
